Caitlyn E. Bowman

This study identifies that SGLT2 inhibitors activate pantothenate kinase 1 (PANK1) in the human heart, enhancing coenzyme-A synthesis and fuel use, which may explain their clinical benefits in heart failure.

This study shows HIF2α prevents GLS1 clustering in mitochondria, protecting ccRCC cells from glutamine deprivation, and suggests targeting GLS1 clustering could enhance HIF2 therapy.

This study shows that BT2, an inhibitor of BCKDK, reduces plasma tryptophan by displacing it from albumin, revealing an off-target effect on tryptophan metabolism.

This study shows that SGLT2 inhibitors improve heart failure in mice independently of their metabolic effects, even when SGLT2 is absent.